You are here

Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria

Last updated on December 17, 2017

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bacterial Infections, Gram-Positive Bacterial Infections, Bacteremia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
13+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients with a central indwelling catheter with signs and symptoms of infection

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with tunneled catheter which cannot be removed.

- Patients with evidence of endovascular infection including endocarditis.

- Patients with infection of permanent intravascular devices.

- Patients who have received more than 1 day of another antibiotic before enrollment.

- Patients with HIV and low CD4 count.

NCT00037050
Pfizer
Completed
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Meningococcal Infections
NCT01900899
All Genders
0+
Years
Multiple Sites
Pneumococcal Infections
NCT03313050
All Genders
50+
Years
Multiple Sites
Candidemia, Peritonitis) Other Forms of Candida Infections(Intra-abdominal Abscess
NCT00802854
All Genders
0+
Years
Multiple Sites
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram-Positive Bloodstream Infections
This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Bacterial Infections
  • Gram-Positive Bacterial Infections
  • Bacteremia
  • Drug: Linezolid
    Other Name: Zyvox
  • Drug: Vancomycin
  • Drug: Oxacillin
  • Drug: Dicloxacillin
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
739
July 2005
Not Provided

Inclusion Criteria:

  • Patients with a central indwelling catheter with signs and symptoms of infection

Exclusion Criteria:

  • Patients with tunneled catheter which cannot be removed.
  • Patients with evidence of endovascular infection including endocarditis.
  • Patients with infection of permanent intravascular devices.
  • Patients who have received more than 1 day of another antibiotic before enrollment.
  • Patients with HIV and low CD4 count.
Sexes Eligible for Study: All
13 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Argentina,   Australia,   Austria,   Belgium,   Brazil,   Chile,   Colombia,   Czech Republic,   France,   Germany,   Greece,   Guatemala,   Hungary,   India,   Ireland,   Italy,   Mexico,   Pakistan,   Panama,   Peru,   Philippines,   Poland,   Portugal,   Russian Federation,   Slovakia,   South Africa,   Spain,   Thailand,   Turkey,   United States,   Venezuela
 
NCT00037050
M12600080
A5951060
Not Provided
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2009

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now